Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 16/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 15/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 12/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | UBE2N | P61088 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12615758 | 0.83 | PIM1 (0.57) | PIM1PIM2PIM3L3MBTL1HTR6 | |
| SCHEMBL12615966 | 0.81 | PIM1 (0.57) | PIM1PIM2PIM3L3MBTL1KDM4E | |
| SCHEMBL12615388 | 0.80 | PIM1 (0.57) | PIM1PIM2PIM3L3MBTL1HTR6 | |
| SCHEMBL12615970 | 0.79 | PIM1 (0.51) | PIM1PIM2PIM3L3MBTL1HTR6 | |
| SCHEMBL12614998 | 0.79 | PIM1 (0.58) | PIM1PIM2PIM3L3MBTL1 | |
| SCHEMBL12616328 | 0.78 | PIM1 (0.57) | PIM1PIM2PIM3L3MBTL1HTR6 | |
| SCHEMBL12614856 | 0.78 | PIM1 (0.47) | PIM1PIM2PIM3L3MBTL1 | |
| SCHEMBL12614840 | 0.78 | L3MBTL1 (0.45) | PIM1PIM2PIM3L3MBTL1HTR6 | |
| SCHEMBL12615334 | 0.77 | L3MBTL1 (0.40) | PIM1PIM2PIM3L3MBTL1HTR6 | |
| SCHEMBL12615851 | 0.77 | PIM1 (0.42) | PIM1PIM2L3MBTL1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321756-B2 | Azole compounds as PIM inhibitors | AMGEN INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | AMGEM INC. (US) | 2014-07-03 | — | — | US | disclosed |
| EP-2688886-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | Amgen Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140187553-A1 | Azole Compounds as PIM Inhibitors | PIM1, PIM3, PIM2 | PIM1 1/4885PIM2 3/4885PIM3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.